Evidence map›Paper›PMID 41595198›Full record

ArticleCancers2026

Modulation of Cancer-Associated Fibroblasts via the miR-624-5p/FAP Axis Drives Progression and Metastasis in Non-Small Cell Lung Cancer.

Yan Zhao, Shuman Zhen, Xiaoxu Li, Xiaolin Chen, Xue Zhang, Xinming Zhao, Lihua Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan ZhaoDepartment of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Shuman ZhenDepartment of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.ORCID 0000-0002-2095-1546
Xiaoxu LiDepartment of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xiaolin ChenHebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang 050011, China.ORCID 0009-0007-9623-1266
Xue ZhangDepartment of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xinming ZhaoHebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang 050011, China.
Lihua LiuDepartment of Tumor Immunotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050035, China.

Funding

Hebei Medicine-Research-Enterprise Collaborative Innovation Project LH20250166Hebei Provincial Finance Department Clinical Medicine Talent Development Program ZF2026225Medical Science Research Project of Hebei 20240427Natural Science Foundation of Hebei Province H2024206154
6 · The paper itself

Abstract

backgroundCancer-associated fibroblasts (CAFs) are key mediators of metastatic progression in non-small cell lung cancer (NSCLC). Fibroblast activation protein (FAP) serves as the hallmark of CAF activation. However, the upstream regulation of FAP remains elusive, limiting stroma-targeted therapy development.

methods

results

conclusionsOur findings establish miR-624-5p as a novel upstream regulator that suppresses FAP expression, consequently inhibiting CAF activation and its pro-metastatic function. Targeting the miR-624-5p/FAP axis represents a promising therapeutic strategy for NSCLC metastasis.

Indexed as

68Ga-FAPI-04 PET/CTcancer associated fibroblasts (CAFs)fibroblast activation protein (FAP)metastasismiR-624-5pNSCLC

Identifiers

PMID41595198
PMCPMC12839361

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.